Association of COX2 −765G>C promoter polymorphism and coronary artery disease in Korean population

[21] McCaleb JL(2008)Cyclooxygenase polymorphisms and risk of cardiovascular events: the Atherosclerosis Risk in Communities (ARIC) study Clin Pharmacol Ther 83 52-495

[22] Oates JA(2009)Cyclooxygenase-2 (COX-2) G-765C is a protective factor for coronary artery disease but not for ischemic stroke: a meta-analysis Atherosclerosis 207 492-143

[23] Morrow JD(2006)Protective effect of the G-765C COX-2 polymorphism on subclinical atherosclerosis and inflammatory markers in asymptomatic subjects with cardiovascular risk factors Clin Chim Acta 368 138-1636

[24] Fazio S(2002)Common promoter variant in cyclooxygenase-2 represses gene expression: evidence of role in acute-phase inflammatory response Arterioscler Thromb Vasc Biol 22 1631-5478

[25] Linton MF(2006)765G>C COX-2 polymorphism may be a susceptibility marker for gastric adenocarcinoma in patients with atrophy or intestinal metaplasia World J Gastroenterol 12 5473-70

[26] Cheng I(2019)Association study of the three functional polymorphisms (TAS2R46G > A, OR4C16G > A, and OR4X1A > T) with recurrent pregnancy loss Genes Genom 41 61-408

[27] Liu X(2009)Cyclooxygenase and prostaglandin synthases: roles in plaque stability and instability in humans Curr Opin Lipidol 20 402-1291

[28] Plummer SJ(1999)Augmented expression of cyclooxygenase-2 in human atherosclerotic lesions Am J Pathol 155 1281-10202

[29] Krumroy LM(2000)Cyclooxygenase-2 mediates the cardioprotective effects of the late phase of ischemic preconditioning in conscious rabbits Proc Natl Acad Sci USA 97 10197-1495

[30] Casey G(2001)Why there are two cyclooxygenase isozymes J Clin Invest 107 1491-1201

[21] McCaleb JL(2008)Cyclooxygenase polymorphisms and risk of cardiovascular events: the Atherosclerosis Risk in Communities (ARIC) study Clin Pharmacol Ther 83 52-495

[22] Oates JA(2009)Cyclooxygenase-2 (COX-2) G-765C is a protective factor for coronary artery disease but not for ischemic stroke: a meta-analysis Atherosclerosis 207 492-143

[23] Morrow JD(2006)Protective effect of the G-765C COX-2 polymorphism on subclinical atherosclerosis and inflammatory markers in asymptomatic subjects with cardiovascular risk factors Clin Chim Acta 368 138-1636

[24] Fazio S(2002)Common promoter variant in cyclooxygenase-2 represses gene expression: evidence of role in acute-phase inflammatory response Arterioscler Thromb Vasc Biol 22 1631-5478

[25] Linton MF(2006)765G>C COX-2 polymorphism may be a susceptibility marker for gastric adenocarcinoma in patients with atrophy or intestinal metaplasia World J Gastroenterol 12 5473-70

[26] Cheng I(2019)Association study of the three functional polymorphisms (TAS2R46G > A, OR4C16G > A, and OR4X1A > T) with recurrent pregnancy loss Genes Genom 41 61-408

[27] Liu X(2009)Cyclooxygenase and prostaglandin synthases: roles in plaque stability and instability in humans Curr Opin Lipidol 20 402-1291

[28] Plummer SJ(1999)Augmented expression of cyclooxygenase-2 in human atherosclerotic lesions Am J Pathol 155 1281-10202

[29] Krumroy LM(2000)Cyclooxygenase-2 mediates the cardioprotective effects of the late phase of ischemic preconditioning in conscious rabbits Proc Natl Acad Sci USA 97 10197-1495

[30] Casey G(2001)Why there are two cyclooxygenase isozymes J Clin Invest 107 1491-1201